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Background: Early combination antiretroviral therapy (cART) reduces the size of the viral reservoir in paediat-
ric and adult HIV infection. Very early-treated children may have higher cure/remission potential.
Methods: In an observational study of 151 in utero (IU)-infected infants in KwaZulu-Natal, South Africa,
whose treatment adhered strictly to national guidelines, 76 infants diagnosed via point-of-care (PoC) testing
initiated cART at a median of 26 h (IQR 1838) and 75 infants diagnosed via standard-of-care (SoC) labora-
tory-based testing initiated cART at 10 days (IQR 813). We analysed mortality, time to suppression of virae-
mia, and maintenance of aviraemia over the first 2 years of life.
Findings: Baseline plasma viral loads were low (median 8000 copies per mL), with 12% of infants having
undetectable viraemia pre-cART initiation. However, barely one-third (37%) of children achieved suppression
of viraemia by 6 months that was maintained to >12 months. 24% had died or were lost to follow up by 6
months. Infant mortality was 9.3%. The high-frequency virological failure in IU-infected infants was associ-
ated not with transmitted or acquired drug-resistant mutations but with cART non-adherence (plasma cART
undetectable/subtherapeutic, p<0.0001) and with concurrent maternal cART failure (OR 15.0, 95%CI
5.639.6; p<0.0001). High-frequency virological failure was observed in PoC- and SoC-tested groups of
children.
Interpretation: The success of early infant testing and cART initiation strategies is severely limited by subse-
quent cART non-adherence in HIV-infected children. Although there are practical challenges to administering
paediatric cART formulations, these are overcome by mothers who themselves are cART-adherent. These
findings point to the ongoing obligation to address the unmet needs of the mothers. Eliminating the particu-
lar barriers preventing adequate treatment for these vulnerable women and infants need to be prioritised in
order to achieve durable suppression of viraemia on cART, let alone HIV cure/remission, in HIV-infected
children.
Funding:Wellcome Trust, National Institutes of Health.
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Initiation of combination antiretroviral therapy (cART) early in
HIV infection reduces the size of the viral reservoir, estimated by the
frequency of HIV DNA in peripheral blood cells, both in paediatric
and adult infection [13]. Low proviral DNA load is the most consis-
tent correlate of cure/remission [3]. However, additional factors other
than limiting the viral reservoir via early cART initiation, including
immune, host genetic, virological and environmental factors, are
likely to influence the ability to achieve cure/remission [2,4,5].
There is some albeit limited evidence that the potential to
achieve cure/remission may be greatest in children following in
utero (IU) infection [1]. Point-of-care (PoC) testing and cART initia-
tion can be implemented very soon after birth [6], and, therefore,
very soon after infection, since most IU infections arise late in preg-
nancy [7]. Furthermore, the tolerogenic immune response in early
life mitigates against immune activation [4]. This contrasts with the
aggressive immune response to HIV in adults which, although bet-
ter at suppressing viral replication, also results in detrimental
immune activation and inflammation [8], accelerating establish-
ment of the viral reservoir.
Several anecdotal cases of cure/remission in early cART-treated
children further support the notion that initiation of cART within the
first days of life might pave the way to achieving cure/remission in a
substantial proportion of those treated [911]. However, a recent
study in South Africa suggests that outcomes in early-treated IU-
infected infants are not successful [6]. To further explore the factors,
including cART non-adherence and drug resistance, underlying suc-
cess or failure of early cART in this group, we studied IU-infected
infants enroled from hospitals in KwaZulu-Natal, South Africa where
the prevention of mother-to-child transmission (PMTCT) programme
has been very effective. IU-MTCT rates have fallen from 7% to 0.5%
since the provision of cART to all HIV-infected mothers during preg-
nancy [1,12] but HIV seroprevalence in mothers attending antenatal
clinics has continued to rise even since the introduction of cART in
2004, and approaches 40% [13]. This setting therefore provided the
opportunity to evaluate the success of early cART on outcome follow-
ing IU-infection.
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2.1. Study design and participants
Ucwaningo Lwabantwana (meaning ‘Learning from Children’) is
an ongoing observational prospective cohort study designed to deter-
mine the feasibility of very early (<48 h of life) cART initiation for IU
HIV-infected infants. In 2015, the study began to identify IU HIV-
infected infants from four secondary-level hospitals in KwaZulu-
Natal, South Africa. In this setting, there is lifelong cART for pregnant
women and routine infant birth HIV total nucleic acid (TNA) PCR.
Baseline results from this current cohort were compared to IU
HIV-infected infants from a historical cohort set in Durban in Kwa-
Zulu-Natal in 20022005 (PEHSS, Paediatric Early HAART and Strate-
gic Treatment Interruption Study) [14,15]. At that time, there was no
ART available to treat adults for HIV infection and perinatal ART pro-
phylaxis was single dose nevirapine (NVP) for both mother and
infant. Raw data from the PEHSS cohort were available for all
50 mother/IU HIV-infected infant pairs at baseline.
2.2. Ethics
These studies were approved by the Biomedical Research Ethics
Committee of the University of KwaZulu-Natal and the Oxfordshire
Research Ethics Committee. Written informed consent for the infant
and mother’s participation in the study was obtained from the
mother or infant’s legal guardian.
2.3. Study definitions
High-risk mother: one or more of the following criteria during
pregnancy; maternal seroconversion, <4 weeks of maternal cART
prior to delivery, suboptimal cART adherence by history or a docu-
mented plasma viral load >1000 HIV RNA copies per mL.
Maternal seroconversion: a documented negative rapid HIV-1
antibody test in pregnancy followed by a positive result later in preg-
nancy or at delivery.
cART non-adherence: missing three or more consecutive cART
doses.
In utero HIV-infected: an infant with a positive or indeterminate
TNA PCR taken <48 h of age that was later confirmed positive via fur-
ther testing from a separate blood samples i.e. in all cases diagnosis
required two or more positive nucleic acid tests.
Viral suppression: Plasma HIV RNA level below the limit of detec-
tion (<20 or <100 HIV RNA copies per mL depending on sample vol-
ume) on one occasion.
Viral rebound: Plasma HIV RNA >1000 copies per mL on one
occasion or two consecutive measurements >100 HIV RNA copies
per mL following viral suppression.
Loss to follow-up: an infant that did not return to the study site
for 6 months despite active tracing.
2.4. Procedures
For the Ucwaningo Lwabantwana study, HIV-positive mothers were
screened after delivery to assess risk of IU HIV transmission. Infants of
high-risk mothers were tested for HIV-1 as soon as possible after birth
using PoC TNA PCR on whole blood (GeneXpert Qualitative HIV-1 PCR,
Cepheid, Sunnyvale, CA, USA) or where PoC testing was not available,
by overnight plasmaHIV RNA viral loadmeasurement (Nuclisens EasyQ
v2.0 HIV-1 RNA PCR, bioMerieux, Marcy l’Etoile, France). The results of
these tests were binary with no indeterminate range.
Infants from the same hospitals who either declined PoC testing or
who were discharged before they could be tested, and those born at
the hospitals’ local clinics with a positive or indeterminate result from
the standard-of-care (SoC) laboratory-based dried blood spot TNA PCR(COBAS AmpliPrep /COBAS TaqMan HIV-1 Qualitative PCR v2, Roche
Molecular Diagnostics, Basel, Switzerland) at birth were also enroled.
Turnaround time for the SoC test result was approximately 47 days.
In all cases diagnosis required two or more positive HIV nucleic acid
tests. Eligibility criteria for enrolment via any method of testing
included an IU HIV-infected infant initiated on cART 21 days of life.
All HIV exposed infants were given prophylactic ART as soon as
possible after birth, consisting of at least daily NVP, and additional
twice daily zidovudine (AZT) for infants deemed high risk of HIV-1
infection, in accordance with the South African National PMTCT Guide-
lines. After the first positive infant HIV-1 test result was received,
blood for confirmatory testing and baseline measurements was taken
and cART consisting of twice daily NVP, AZT and lamivudine (3TC) was
initiated as per local guidelines. This neonatal regimen was switched
to ritonavir-boosted lopinavir (LPVr), 3TC and abacavir (ABC) at 42
weeks corrected gestational age or at 1 month of age.
Mother and infant follow-up occurred monthly for 6 months then
3 monthly. At each visit, blood was drawn for CD4+ T cell quantifica-
tion, plasma viral load (HIV-1 RNA PCR, NucliSens), and storage of
peripheral blood mononuclear cell (PBMC) and plasma.
During follow-up, additional support was provided for the care-
givers, including regular one-on-one counselling sessions from
trained HIV counsellors in the local language (isiZulu), paid transport
to clinic, appointment reminders via phone, family support groups
and home visits where required.
Stored PBMC and plasma samples were used for additional confir-
matory testing, and where available, for the quantification of drug
resistance mutations (DRMs) by Next Generation sequencingmethods,
HIV DNA by droplet digital PCR (ddPCR; BioRad, Hercules, California,
USA), and plasma ART levels by high performance liquid chromatogra-
phy coupled to tandemmass spectrometry (Supp. Methods).
2.5. Analysis and outcomes
To assess the feasibility and impact of very early cART initiation in
this current cohort, Ucwaningo Lwabantwana, we considered out-
comes for the whole cohort of IU HIV-infected infants together and
then compared two subgroups of IU-infected infants according to the
timing of test they were first identified by: the PoC and SoC groups.
Comparisons included: time to cART initiation, maternal and infant
baseline characteristics, time to viral suppression, viral rebound rates,
mortality, loss to follow-up and viral suppression rates at 12 and 24
months. To assess the influence of drug resistance on virological out-
comes, DRMs were quantified and plasma ART levels were measured
to evaluate potential non-adherence to treatment. To assess the impact
of the current PMTCT programme, these infants’ baseline results were
also compared to those infants from the historical PEHSS cohort.
2.6. Statistical analysis
Clinical and laboratory results were described using absolute num-
bers, percentages, medians and interquartile range (IQR). Comparisons
were performed using the Chi-Squared and Fisher’s exact tests for cate-
gorical variables and the Mann-Whitney U test for continuous varia-
bles. Mortality rate, viral suppression and viral rebound were
calculated in univariate analyses using Kaplan-Meier curves and groups
were compared using the Log-Rank test. Because of the large number
(25) of candidate mother-child variables at baseline, predictors of mor-
tality, viral suppression and viral rebound were analysed in multivari-
ate analyses using a penalised Cox regression model, where the set of
relevant predictors was selected by the LASSO penalty approach [16]
and the optimal penalty parameter ξ was determined via 10-fold cross
validation using the glmnet R package [17]. A sensitivity analysis was
carried out by using an alternative definition of viral rebound; the date
the plasma viral load exceeded HIV RNA 1000 copies per mL. The rela-
tionship between maternal and infant viral loads was calculated using
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Calculations and graphs were performed using R Software v3.6.1 and
GraphPad Prism v8 respectively.
3. Role of the funding source
The funders of this study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report. The
corresponding author had full access to all the data in the study and
had final responsibility for the decision to submit for publication.
4. Results
Between July 01, 2015 and January 31, 2019, 151 IU-infected
infants were enroled onto the Ucwaningo Lwabantwana study (Fig 1,
Table 1). In all 151 cases, infant ART prophylaxis was initiated within
minutes of birth prior to diagnosis of IU infection. Two-thirds of
infants (103/151, 68%) received both NVP and AZT, the remaining
one-third (48/151, 32%) receiving NVP or AZT only. Of these 151 IU-
infected infants, 76 were identified through PoC (n = 70) or overnight
viral load (n = 6) testing of infants, and cART was initiated at a median
age of 26 h (IQR 1838). A further 75 infants were diagnosed through
SoC testing, in whom cART was initiated at a median age of 10 days
(IQR 813). ART prophylaxis did not differ significantly between the
PoC and SoC groups (Table 1).Fig. 1. Study Profile.
✟ High risk; during pregnancy the mother either seroconverted, had <4 weeks cART, poo
per mL.
*Tested with point-of-care (PoC) whole blood GeneXpert (GXP) HIV-1 Qualitative total
plasma Nuclisens EasyQ v2¢0 HIV-1 RNA PCR (bioMerieux).
✦Laboratory-based dried blood spot TNA PCR (CAP/CTM HIV-1 Qualitative Test v2 Roche)
**iLembe, uMgungundlovu, eThekwini and uThungulu districts.
✟ ✟Confirmatory testing included; TNA PCR via CAP/CTM or GXP, HIV RNA PCR via Nuclise
IU: in utero, cART: combination antiretroviral therapy.With respect to timing of maternal infection, 31% (47/151) of the
IU-infected infants were born to mothers designated as seroconvert-
ing during the pregnancy. This included 41 mothers who had a nega-
tive HIV test during pregnancy followed subsequently by a positive
test; and 6, in whom the estimated seroconversion date, midway
between last negative test and first positive test, was also during
pregnancy. In 28% (42/151) of cases, the infants were born to mothers
known to have been HIV-infected prior to conception, including 6
who were themselves infected via MTCT (Table 1). The remaining 62/
151 (41%) mothers’ first HIV test during the pregnancy was HIV-posi-
tive and the timing of infection was unknown (Table 1). Due to lack-
ing antenatal care, or seroconversion late in pregnancy, cART had not
been initiated in 25% (37/151) of mothers prior to the onset of labour.
amongst the 75% (114/151) of mothers who initiated cART prior to
the onset of labour, 63 (55%) self-reported poor cART adherence, of
which nine (8%) omitted all doses. Timing of maternal infection and
maternal cART initiation did not differ between the PoC and SoC
groups (Table 1).
The majority of IU-infected infants were healthy, term babies
(median gestation 38 weeks [IQR 3639], median birth weight
2.82 kg [IQR 2.43.14]) (Table 1). However, 32/151 (21%) were small-
for-gestational age (birth weight <10th centile on InterGrowth 21st
charts [18] and 46/151 (31%) of infants required hospital admission
in the first 28 days of life. As previously reported [19], the number of
female IU-infected infants exceeded that of males (96 vs 55). Forr cART adherence by history or a documented plasma viral load >1000 HIV RNA copies
nucleic acid (TNA) PCR (Cepheid); but when not available an overnight HIV RNA test;
ns or in selected cases more sensitive methods.
Table 1
Demographic and clinical information of mother and in utero HIV-infected infant pairs at baseline.
All Point-of-care Tested Standard-of-care Tested
(n = 151) (n = 76) (n = 75)
MOTHER IQR/% IQR/% IQR/% P-value of PoC vs SoC
Median maternal age (years) 24.7 (21.530.0) 24.1 (21.427.9) 26.3 (21.427.9) 0.088
Timing of maternal HIV infection .. .. .. .. .. .. ..
Chronic; vertical 6 4.0% 3 4.0% 3 4.0% 0.41
Chronic; horizontal 36 23.8% 14 18.4% 22 29.3% ..
Acute 47 31.1% 27 35.5% 20 26.7% ..
Unknown 62 41.1% 32 42.1% 30 40.0% ..
Previous MTCT 7 4.6% 4 5.3% 3 4.0% 1.0
Median number of other children 1 (02) 1 (02) 1 (02) 0.25
Timing of maternal cART initiation .. .. .. .. .. .. ..
Pre-pregnancy 31 20.5% 13 17.1% 18 24.0% 0.33
During pregnancy >12 weeks prior to delivery 50 33.1% 26 34.2% 24 32.0% ..
During pregnancy <12 weeks prior to delivery 33 21.9% 16 21.1% 17 22.7% ..
During labour or at delivery 20 13.2% 14 18.4% 6 8.0% ..
Postnatally 17 11.3% 7 9.2% 10 13.3% ..
Maternal cART regimen at enrolment .. .. .. .. .. .. ..
1st line (NNRTI) 146 96.7% 75 98.7% 71 94.7% 0.30
2nd line (PI) 3 2.0% 1 1.3% 2 2.7% ..
None* 2 1.3% 0 0% 2 2.7% ..
Self-reported antenatal cART non-adherence or refusaly 63 55.3% 30 54.5% 33 55.9% 0.69
Median plasma viral load (HIV RNA copies per mL) 4400 (52040 500) 12 500 (1400160 000) 2200 (13312 500) 0.0002
Median absolute CD4+ T cell count (cells/mL) 452 (318637) 442 (298604) 462 (348641) 0.45
Median CD4:CD8 0.46 (0.310.69) 0.44 (0.300.62) 0.5 (0.340.75) 0.10
INFANT .. .. .. .. .. .. ..
Sex .. .. .. .. .. .. ..
Male 55 36.4% 20 26.3% 35 46.7% 0.011
Female 96 63.6% 56 73.7% 40 53.3% ..
Median Gestation at birth (weeks)z 38 (3639) 37 (3639) 38 (3640) 0.24
Median Birth weight (kg) 2.82 (2.403.14) 2.81 (2.363.09) 2.86 (2.503.20) 0.44
Small for gestational agez,x 32 21.2% 16 21.1% 16 21.3% 1.00
Exclusively breastfed 120 79.5% 69 90.8% 51 68.0% 0.0011
Neonatal admission{ 46 30.5% 23 30.3% 23 30.7% 1.00
Infant ART prophylaxis 151 100% 76 100% 75 100% 1.0
Nevirapine only 47 31.1% 26 34.2% 21 28.0% 0.45
Zidovudine only 1 0.7% 0 0.0% 1 1.3% ..
Nevirapine and Zidovudine 103 68.2% 50 65.8% 53 70.7% ..
Median plasma viral load (HIV RNA copies per mL) 8350 (150067 500) 29 500 (3325342 500) 3350 (30022 500) <0.0001
Median absolute CD4+ T cell count (cells permL) 2035 (12632700) 1682 (10122299) 2444 (18113147) <0.0001
Median CD4+ T cell percentage 43 (3552) 39 (31.849.5) 46 (3753) 0.011
Median CD4:CD8 1.86 (1.132.84) 1.54 (1.052.65) 2.08 (1.363.21) 0.043
Standard-of-care TNA PCR birth test result .. .. .. .. .. .. ..
Positive 136 90.1% 66 86.8% 70 93.3% 0.25
Indeterminate 13 8.6% 8 10.5% 5 6.7% ..
Negative 2 1.3% 2 2.6% 0 0% ..
Age of cART initiation (hours or days) 4d (26h10d) 25.6h (17.737.9 h) 10d (813d) <0.0001
MTCT: mother-to-child transmission, NNRTI: non-nucleoside reverse transcriptase inhibitor, PI: protease inhibitor, cART: combination antiretroviral therapy.
* Two mothers had cART initiation delayed beyond enrolment while TB infection was excluded.
y Of those who initiated cART prior to labour.
z 6 infants had unknown gestational age at birth.
x As classified by InterGrowth 21st charts.
{ Direct to neonatal ward or to the paediatric ward aged  28 days of life.
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in the PoC group (females:males 2.8:1) compared to the SoC group
(females:males 1.1:1; p = 0.011) (Table 1).
The first (‘baseline’) measurements of plasma viral load and CD4+
T cell count in the PoC and SoC groups were taken, respectively, at a
median of 1 day and 10 days of age, and thus after 1 and 10 days of
prophylactic ART (NVP alone or AZT/NVP). As expected, therefore, at
baseline, the SoC infant group had significantly lower plasma viral
loads than the PoC group (median 3350 vs 29 500 HIV RNA copies per
mL; p<0.0001), higher CD4+ T cell counts (median 2444 vs 1682 cells
per uL; p<0.0001) and higher CD4+ T cell percentage, (median 46%
versus 39%, p = 0.01; Fig 2AC). However, by 1 month of age, differen-
ces between the PoC and SoC groups in plasma viral load, absolute
CD4+ T cell count and CD4+ T cell percentage had disappeared (Fig
2AC).
Baseline infant plasma HIV viral loads were significantly lower
and absolute CD4+ T cell counts significantly higher in the current
Ucwaningo Lwabantwana cohort of 151 IU-infected infants comparedto the 20022005 PEHSS cohort of 50 IU-infected infants, also in
KwaZulu-Natal, South Africa (Fig 2DF), when cART was not avail-
able to mothers during pregnancy. Similarly, in the IU transmitting
mothers, plasma viral loads were lower in the current Ucwaningo
Lwabantwana cohort compared to the PEHSS cohort (4400 vs 39 700
RNA copies per mL p<0.0001, Fig. 2G). In the 23 mothers from the
Ucwaningo Lwabantwana cohort who had no ART prior to labour and
plasma viral load measurement within 1 week of delivery, plasma
viral load was similar to the PEHSS cohort (16 000 vs 39 700 HIV RNA
copies per mL, p = 0.09, not shown). It is noteworthy that as many as
19/151 (12.5%) of the Ucwaningo Lwabantwana cohort of IU-infected
infants had undetectable plasma viral loads (<20 HIV RNA copies per
mL or <100 HIV RNA copies per mL) at baseline, consistent with the
notion that, in the majority of IU-infected infants, there is significant
intrauterine ART exposure transplacentally.
To investigate further whether delaying cART initiation to day 10
compared to initiation on day 1 of life might affect the size of the viral
reservoir in the PoC and SoC groups of infants at the time of cART
Fig. 2. Effects of very early ART initiation and universal maternal cART on baseline plasma HIV viral load and CD4+ T cell count. (A) Plasma HIV RNA viral load, (B) absolute CD4+ T
cell count and (C) CD4+ T cell percentage of the IU HIV-infected infants at baseline (<21 days of life, prior to combination antiretroviral therapy (cART) initiation) (left) and at 1
month of age (right), where PoC were diagnosed using a point-of-care HIV TNA PCR or overnight RNA PCR test and treated very early (median age 26 h) and SoC were diagnosed by
the standard-of-care laboratory-based HIV PCR test and treated early (median age 10 days). (D) Plasma HIV RNA viral load, (E) absolute CD4+ T cell count and (F) CD4+ T cell percent-
age of the IU HIV-infected infants within 21 days of birth where 20152019 is the current cohort (Ucwaningo Lwabantwana) and 20022005 are the cohort from the same popula-
tion prior to universal antenatal cART (PEHSS). (G) Plasma HIV RNA viral load, (H) absolute CD4+ T cell count and (I) CD4+ T cell percentage of the mothers of the IU HIV-infected
infants shown in figure D-F, within a month of delivery. Median values and interquartile range displayed. All p-values calculated using the Mann-Whitney U test.
Fig. 3. Baseline infant proviral HIV DNA levels compared to plasma RNA. Baseline infant
plasma HIV RNA levels (copies per mL) (left) and proviral HIV DNA levels (copies per mil-
lion peripheral blood mononuclear cells (PBMC)) as measured by droplet digital PCR
(right) for a subset of infants at baseline, a comparison for PoC, diagnosed by point-of-care
test and treated very early (median time 26 h) and SoC, those diagnosed by standard-of-
care laboratory-based test and treated early (median time 10 days). Median values and
interquartile range displayed. Open symbols are below the limit of detection (20 or 100
copies per mL for RNA and variable for each individual test for DNA (210 copies per mil-
lion PBMC). P-values calculated using theMann-Whitney U test.
6 J.R. Millar et al. / EClinicalMedicine 22 (2020) 100344initiation, HIV DNA viral loads were measured by ddPCR in a subset of
35 infants, selected according to sample availability. Even though the
plasma HIV RNA loads were 1.21.3 log10 higher in the PoC group,
HIV DNA viral loads measured at the same timepoint showed mini-
mal difference between the groups (<0.07 log10 copies HIV DNA per
million PBMC; p = 0.43, Fig 3). Together with the data showing a lack
of difference in plasma viral loads between the PoC and SoC groups at
1 month of age, these findings suggest that SoC testing and cART initi-
ation at median 10 days does not bring any significant disadvantage
compared with PoC testing and cART initiation at median 26 h in a
setting where prophylactic ART is initiated in all babies born to HIV-
positive mothers within minutes of birth and ART exposure com-
monly occurs in utero.
To assess initial outcome in SoC and PoC-treated, IU-infected
infants, we next evaluated the 114/151 infants from the Ucwaningo
Lwabantwana cohort who were born 12 months prior to the time
of analysis. Excluding four infants (two PoC- and two SoC-tested)
who transferred out in the first week of life to receive care at external
clinics, 26 of the remaining 110 (24%) had either died (n = 8, 7.3%), or
were lost to follow-up (n = 18, 16.4%) (Fig 4A). amongst the latter, six
died subsequent to defaulting clinic appointments. Thus, in the
cohort overall (n = 151), 15 infants died. The probability of death by
age 3 months was 6.4% (95% CI 2.310.3%) and was 9.3% by 1 year
(95% CI 4.414.1%; not shown) with a median age of death of 3.5
months. The multivariate analysis identified three independent
Fig. 4. Infant outcomes: retention, mortality and plasma viral suppression. (A) Proportions of infants with the opportunity for 12 months follow-up (excluding 4 infants who were
withdrawn by the investigators) who died, were lost to follow-up, those who did not achieve plasma viral suppression by 6 months of age, those who did achieve plasma viral sup-
pression by 6 months of age but had rebounded by 12 months of age, and those who achieved plasma viral suppression by 6 months of age and maintained suppression to at least
12 months of age. (B) Kaplan-Meier analysis of time to plasma viral suppression; a comparison of PoC and SoC groups. PoC infants were diagnosed using a point-of-care HIV TNA
PCR or overnight RNA PCR test and treated very early (median time 26 h) and SoC are those diagnosed by the standard-of-care laboratory based HIV PCR test and treated early
(median time 10 days). (C) Kaplan-Meier analysis of time to plasma viral rebound; a comparison of PoC and SoC groups.
J.R. Millar et al. / EClinicalMedicine 22 (2020) 100344 7predictors of mortality: low infant birthweight; neonatal hospital admis-
sion and high infant baseline plasma HIV RNA viral load (Supp. Tab. 1).
Of the infants retained on the study at 12 months of age, 15/110
(13.6%) had not achieved suppression of plasma viraemia on cART by
6 months and 28/110 (25.5%) had achieved only short-term suppres-
sion of viraemia, rebounding by 12 months (Fig 4A). Only 37.3% of
the 110 IU-infected infants enroled had achieved and maintained
suppression of viraemia on cART to 12 months of age. 40 out of the
84 infants on the study at 12 months were also analysed 24 months
post-enrolment. 14/17 (82.4%) of those infants who had suppressed
by 6 months and maintained suppression to 12 months, continued to
maintain viraemic suppression to 2 years of age. In contrast, only 2/
17 (12%) of those whom only had short term suppression between 6
and 12 months, and 0/6 of those who had not supressed by 6 months,
achieved and maintained suppression to 2 years (Supp. Fig. 1).
In order to further investigate why sustained suppression of virae-
mia in early-treated infants on ART is so infrequent, we first com-
pared the PoC and SoC groups. Although there was no difference inmortality or retention on the study at 12 months (p = 0.75, and
p = 0.19, respectively), in the univariate analyses, infants in the SoC
group tended to achieve suppression of viraemia earlier, and to main-
tain suppression of viraemia longer than those in the PoC group (Fig
4BC, p = 0.25 and p = 0.03, respectively). These findings held true in
the multivariate analyses, with a strong predictor at baseline for
rebound being the PoC group compared with the SoC group, Supp
Table 1. The strongest predictive factor at baseline for time to viral
suppression was baseline infant plasma viral load and was not influ-
enced by the age at which the infant initiated cART. Aside from SoC
vs PoC group influencing time to infant viral rebound, longer duration
of maternal cART in pregnancy and older infant gestational age at
birth was also found to be associated with a faster rate of rebound,
while older maternal age, male infants, and being admitted to hospi-
tal in the neonatal period was associated with a slower rate (Supp.
Table 1). There was no significant change to the rate of viral rebound
when relaxing the definition of viral rebound to a level >1000 HIV
RNA copies per mL only (Supp Fig 2). High rates of treatment failure
Table 2
Mother and infant transmitted drug resistance genotype and phenotype.









(RNA copies per mL) NNRTI NRTI PI Intermediate High
Infant age at viral
supp-ression (m)
1 Mother 1 1 0 6300 none none none none none ..
Child 1 0 0 4600 none none none none none 1
2 Mother 9 150 141 100 000 none none none none none ..
Child 9 0 141 830 none none none none none 1
3 Child 9 0 0 3400 K103N (100%) none none none EFV, NVP 2
4 Mother 1 >5 years >5 years 13 000 K103N (77%), Y188L (25%) none none none EFV, NVP ..
Child 1 0 >5 years 150 000 Y188L (99%) none none none EFV, NVP 2
5 Child 1 34 33 3900 none none none none none 5
6 Mother 12 17 years 17 years 2800 none none none none none ..
Child 53 41 17 years 36 000 Y181C (98%) none none EFV NVP 5
7 Child 1 0 159 430 0000 K103N (100%) none none none EFV, NVP 6
8 Mother 1 0 0 1 100 000 none none none none none ..
Child 28 28 28 53 000 none none none none none 5
9 Mother 18 8 years 8 years 3400 K103N (20%) none none none EFV, NVP ..
Child 18 0 8 years 32 000 K103N (45%), V106A (29%),
G190A (22%)
none none none EFV, NVP 27
10 Mother 11 37 26 28 000 K103N (66%) none none none EFV, NVP ..
Child 60 49 26 57 000 K103N (98%), V106A (28%),
Y188C (22%)
none none none EFV, NVP >18
11 Child 90 88 245 450 000 K103N (86%), A98G (99%) none none none EFV, NVP >18
12 Mother 2 4 2 16 000 none none none none none ..
Child 2 0 2 1 500 000 none none none none none LTFU at 1
13 Mother 0 203 203 770 000 none none none none none ..
Child 0 0 203 2 900 000 none none none none none died at 8
14 Mother 2 0 0 43 000 none none none none none ..
Child 2 0 0 350 000 none none none none none LTFU at 15
HIV genotype was determined using Next-Generation Sequencing methods for mother and infant pairs at baseline, subject to sample availability. Drug resistance mutation (DRM)
prevalence shown in brackets. Resistance phenotype for the antiretroviral drugs commonly used in South Africa were determined from the Online Stanford Database. Median
infant age at blood draw was 5.5 days (IQR 126 days). Participants listed in order of increasing time to infant plasma viral suppression (in months). No nucleoside reverse tran-
scriptase inhibitor (NRTI) or protease inhibitor (PI) resistance mutations were found for any of the participants. NNRTI: non-nucleoside reverse transcriptase inhibitor, NVP: nevi-
rapine, EFV: efavirenz.
8 J.R. Millar et al. / EClinicalMedicine 22 (2020) 100344suggest either inferior cART adherence or reduced cART effectiveness
due to drug resistant mutations (DRMs).
To investigate whether ART resistance might explain the high rates
of virological failure on ART in the Ucwaningo Lwabantwana cohort,
we first addressed the question of whether drug resistant mutations
(DRMs) were transmitted from the mother to the child. Samples from a
subset of infants (n = 14, selected according to sample availability) were
deep sequenced for DRMs at baseline (median age 5.5 days [IQR 126
days], Table 2). amongst these 14 infants, seven achieved suppression
of viraemia by 6 months of age, in three cases without any DRMs
detected, and in the remainder with only one NNRTI DRM detected in
the child’s virus. amongst the seven infants who did not achieve sup-
pression of viraemia by 6 months, four had no detectable DRMs and
the remaining three had two or three NNRTI DRMs at baseline corre-
sponding to high-level resistance to NVP. Given the short duration the
infants receive NVP-based cART before switching to protease inhibitor
(PI)-based cART and the absence of any PI DRMs at baseline, these data
are consistent with ART non-adherence rather than transmitted DRMs
being the cause of virological failure in these children.
We next investigated whether virological failure might have
resulted from DRMs acquired in older infants. Samples were analysed
from a second subset of infants (n = 16, selected according to sample
availability) aged >6 months (median 12 months, IQR 815; median
viral load 24 000 HIV RNA copies per mL) with virological failure,
defined as a plasma RNA viral load of >1000 HIV RNA copies per mL.
We also measured levels of antiretroviral drugs in these 16 plasma
samples, since although ART detection reflects adherence only in the
previous 2448 h, ART non-detection unequivocally demonstrates
non-adherence during this window (Table 3). In four subjects, viral
suppression was never achieved, and no DRMs were detected in the
viruses. Three of these subjects had no ART detectable, and one only
3TC, consistent with poor or no ART adherence. In the remaining 12subjects, eight had high-level 3TC resistance. However, in nine of
these 12, virological failure was matched by absence of cART detect-
able in the plasma, and six of nine infants who were not subsequently
lost to follow up later suppressed viraemia on the same regimen of
ABC/3TC/LPVr. This suggests that, in the absence of PI DRMs, adher-
ence to this regimen can still achieve viral suppression.
To test further the hypothesis that children with virological failure
were cART non-adherent, we compared plasma ART levels in children
with virological failure (n = 16, Table 3) with children maintaining
suppression of viraemia who by history were ART-adherent (n = 11).
All 11 of the virally suppressed infants had all three prescribed ART
drugs detectable at high levels in the plasma, while 13/16 (81%) of
the infants with high viral loads had either no or only one ART drug
detected at therapeutic levels (p<0.0001, Fig. 5A, Table 3). Together,
these analyses indicate that the high frequency of failure to achieve
suppression of viraemia on cART in the Ucwaningo Lwabantwana
cohort of IU-infected infants is principally due to non-adherence.
Finally, in 101 children older than 6 months of age who had a
plasma viral load measurement at the same time point as their mother,
viral suppression in the mother and child was strongly associated (OR
15.0, 95%CI 5.639.6; p<0.0001, r = 0.61, 95%CI 0.470.72; p<0.0001)
Fig 5B-D. Together, these data strongly support the conclusion that the
same barriers to effective treatment affect both the mother and child,
and if the needs of the mothers are addressed, then the challenges of
administering ART to children are no longer a significant obstacle pre-
venting ART adherence in the children.
5. Discussion
These studies were designed to explore the impact of early cART
in IU-infected children and the opportunity to facilitate cure/remis-
sion. Initial plasma RNA and DNA viral loads in IU-infected infants
Table 3
Infant drug resistance genotype and phenotype at 12 months.












1 36 17 000 none none none none none none no none
15* 9 15 000 none none none none none none no 3TC
16 15 24 000 none none none none none none no - LTFU none
17 6 410 000 none none none none none none no - LTFU none
18 12 350 000 K103N (88%) none none none none EFV, NVP yes none
19* 9 2100 none M184V none ABC none 3TC yes LPVr, 3TC, ABC
20 6 6500 none M184I (38%) none ABC none 3TC yes none
21 9 520 000 K103N (84%) K65R (98%) M184V (97%) none none none 3TC, ABC, EFV, NVP yes 3TC
9* 15 88 000 Y181C
G190A
M184V none ABC EFV 3TC, NVP yes none
10 6 69 000 K103N (98%)
Y188C (16%)
none none none none EFV, NVP no none
22 6 7400 K103N (87%) none none none none EFV, NVP yes none
23 15 6000 none M184I (96%) none ABC none 3TC no 3TC
11 9 390 000 A98G (98%)
K103N (82%)
M184V (98%) none ABC none 3TC, EFV, NVP no none
14 12 50 000 V106M (72%)
G190A (12%)
F227L (11%)
none none none EFV NVP no - LTFU LPVr, 3TC, ABC
24 12 330 000 K103N (81%) M184V (12%) none ABC none EFV, NVP ABC, 3TC no - LTFU none
25 18 15 000 V106M (91%)
H221Y (98%)
M184V (98%) none ABC EFV 3TC, NVP no - LTFU LPVr, 3TC, ABC
HIV genotype was determined using Next-Generation Sequencing methods of a selection of infants with plasma viral load >1000 RNA copies per mL, subject to sample avail-
ability. Mutation prevalence shown in brackets. *Indicates samples that only underwent Sanger consensus sequencing. Resistance phenotypes for the ART drugs commonly
used in South African children were determined from the Online Stanford Database. Plasma ART levels were quantified using high performance liquid chromatography and
were considered negative if at very low levels or below the level of quantification. Median infant age was 12 months, IQR 815 months; median viral load 24 000 HIV RNA cop-
ies per mL. No protease inhibitor (PI) resistance mutations were found for any of the participants. NNRTI: non-nucleoside reverse transcriptase inhibitor, NRTI: nucleoside
reverse transcriptase inhibitor, ABC: abacavir, 3TC: lamivudine, NVP: nevirapine, EFV: efavirenz, LPVr: ritonavir boosted lopinavir, LTFU: loss to follow-up.
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baseline, suggesting clear potential to ultimately achieve cure/remis-
sion in this group. The findings, however, are striking in highlighting
the high-frequency failure of cART in this group, however early in life
it is delivered. Barely one-third (37%) of cART-treated infants
achieved suppression of viraemia by 6 months that was maintained
beyond 12 months of age. Almost one quarter (24%) of IU-infected
infants either died or were lost to follow-up by 6 months. In the sub-
set tested, high-frequency cART failure did not result from drug-resis-
tant mutations (DRMs). The barriers contributing to treatment failure
are the same in both mother and child. This is an important result
because it means that, if the needs of the mother can be successfully
addressed, the practical challenges of administering cART to children,
in most cases, will also be met. If durable suppression of viraemia in
HIV-infected infants is to be achieved, and the undoubted opportuni-
ties to achieve cure/remission in HIV-infected children are to be fully
realised, the unmet needs of transmitting mothers urgently need to
be addressed first, whilst, at the same time, exploring options for
long-acting or extended-release paediatric ART formulations. Finally,
apparently superior treatment outcomes for the SoC tested group
suggests that barriers to returning to clinic to collect test results
selects out infants with inherently better outcomes, and that
although PoC testing gives the opportunity to capture these vulnera-
ble infants, more focus needs to put into supporting the maintenance
of cART once initiated.
In South Africa, IU-infected infants usually receive cART transpla-
centally in addition to ART prophylaxis (AZT and NVP or NVP alone)
immediately after birth (prior to HIV diagnosis). In this setting, nei-
ther this study nor another South African study by Technau et al. [6]
showed superiority in initiating infant cART (AZT, NVP and 3TC) in
the first 48 h of life following PoC testing and diagnosis, compared
with cART initiation at a median of 10 days following SoC testing and
diagnosis. Indeed, Technau et al. reported worse retention in care for
the PoC tested infants, and here we observed that the SoC tested
infants, who had returned to clinic from home for confirmatorytesting, had higher rates of sustained viral suppression. Together,
these findings suggest that HIV-infected infants successfully recalled
from home following a positive birth test inherently may be more
likely to succeed with treatment. However, the data to determine the
proportion of infected infants successfully recalled were not avail-
able. It is possible that studies only analysing those infants success-
fully recalled may over-estimate positive treatment outcomes. The
ability of PoC testing to initiate ART earlier in perinatally infected
infants has been well-described in a range of African countries [20]
and is demonstrated also here, but in countries such as South Africa
where universal birth testing is already implemented, and where
ART is reaching infected infants transplacentally and at birth via pro-
phylaxis, the advantages of PoC over SoC testing may be reduced. Fur-
thermore, these HIV-infected infants were born to mothers with a
range of immune status and ART exposure, resulting in the wide het-
erogeneity of infant HIV DNA levels at baseline. It is possible that
some of these infants were not in fact, early in infection and perhaps
the relevance of initiating cART in the first hours of life has been over-
stated.
The high rates of treatment failure we present here, along with
other studies describing the difficulties in treating paediatric HIV
infection in sub-Saharan Africa [6,2123], as well as in high-
resourced settings [24,25] suggests a prevailing problem across the
world. Perinatal HIV transmission, whether in high- or low-resourced
settings, is concentrated in the most marginalised populations
[26,27] who are often disengaged from conventional health care pro-
viders. Indeed, the Mississippi child is a case in point [9], whose
remission only came to light following loss to follow up and ART
non-adherence. Here we have found strong evidence showing cART
failure in the child is due to cART non-adherence and is tightly linked
to cART failure in the mother. The magnitude of relationship between
mother and child suppression we found is much higher than has
been recently described in older children [28], showing the critical
role of the mother for consistent cART administration. On exploring
the factors related to rate of infant viral rebound, counterintuitively,
Fig. 5. Determinants of infant plasma viraemia. (A) Results from plasma ART quantification from Table 3 are compared to those of 11 infants of similar age (median age 21 months)
with plasma viral suppression (median duration of suppression 18 months) on cART. Negative levels includes very low levels and levels below the level of detection. P-value calcu-
lated using Fisher’s exact test. 3TC: lamivudine, ABC: abacavir; LPVr: ritonavir boosted lopinavir. (B) Plasma viral load levels over time for a mother-child pair following combination
antiretroviral therapy (cART) initiation, as an example of infant treatment success being determined by maternal cART adherence. Dashed line shows limit of detection (20 HIV RNA
copies per mL). (C) A cross-sectional analysis of 101 mother-child pairs, >6 months on cART at the most recent timepoint of contemporaneous (within 14 days) plasma viral load
measurement for the mother and child. Suppression is defined as a plasma viral load lower than the detectable limit (20 or 100 RNA copies per mL). Odds ratio is shown and p-value
is calculated using Fisher’s Exact test. (D) Spearman’s non-parametric correlation of maternal and infant plasma load shown in (C).
10 J.R. Millar et al. / EClinicalMedicine 22 (2020) 100344the strongest predictive factor was a longer duration of maternal
cART in pregnancy. This could be explained by the mothers who
were prescribed cART prior to pregnancy and defaulted treatment
resulting in transmission in utero, being more likely to have difficulty
administering infant cART compared to mothers who transmitted
simply because they were diagnosed late in pregnancy. Interestingly,
infants born at a younger gestational age and also those admitted to
hospital as a neonate had lower rates of rebound, suggesting that
additional support for the mother in the first weeks of life may be
protective for virological control over the longer term. Older mater-
nal age was also found to be protective against infant viral rebound.
The importance of considering a child in the context of the mother is
nowhere better illustrated than in the setting of perinatal HIV.
Infant mortality at 1 year was 9.3%, similar to other studies of
South African IU HIV-infected infants [6] but high compared to
national estimated infant mortality rate of 2733/1000, albeit a
figure only representing reported deaths, therefore a significant
underestimate [29]. Our figure is also likely to be an underestimate,as the outcome for some of the infants lost to follow-up was
unknown. The predictors of infant mortality were low birth weight,
followed by neonatal hospital admission and baseline infant plasma
viral load, the latter also reported by Technau et al. [6] Change of
caregivers, home environment, comorbidities and other factors that
were not systematically assessed by this study were likely playing
pivotal roles. Moreover, the cause and circumstances of death were
often not ascertained because most of the infants (9/15, 60%) died
either at home or within a few hours of arrival at a hospital. This phe-
nomenon in itself illustrates either the lack of access, poor engage-
ment or mistrust in conventional health care providers. In-depth
qualitative analysis of caregivers’ experiences may illuminate areas
for improvement in provision of care for HIV-infected infants.
It is important to consider the potential limitations within this study.
Most crucially, in our comparisons of outcomes following PoC testing
versus SoC testing, it should be emphasised that this was not a rando-
mised controlled trial. Indeed, there were some differences between the
PoC and SoC groups that were unexpected, such as the proportion of
J.R. Millar et al. / EClinicalMedicine 22 (2020) 100344 11females (74% vs 53%), and the proportion exclusively breast-fed (91%
versus 68%), the clinical significance of which were unclear. With these
differences at baseline, and the outcomes of the SoC tested infants who
were not recruited onto the study unknown, a direct comparison of the
PoC and SoC infants should be interpreted with caution. However, what
is irrefutable, is that despite very early cART initiation, PoC tested
infants’ outcomes are poor. It has been suggested that integrase strand
inhibitor drugs can achieve suppression in early treated infants faster
[25], which could mean that the poor viral suppression rates we
describe will improve with the plannedmove away from paediatric reg-
imens based on the notoriously unpalatable LPVr suspension. However,
the strong association between viral suppression in the mother (taking
one tablet once a day) with viral suppression in the child suggests that if
the mother is cART-adherent, the cART regimen being utilised here in
the children is effective and that unpalatability is not the over-riding
factor causing failure. Although we found no evidence to suggest that
drug resistance accounted for the high-frequency cART failure, our sam-
ple size was small, and we were only able to test children with a high
plasma viral load, so it is possible that in some cases resistance contrib-
uted to cART failure. The direct testing of plasma showing a failure to
detect cART in the majority of children with virological failure argues
against this. Nevertheless, if these children continue to have viraemia
and sub-optimal ART dosing, it is only a matter of time before ART resis-
tance develops and contributes to treatment failure. Finally, our study
was limited by the inability to determine the outcomes for the majority
of infants who did not return to clinic and were lost to follow-up. Due
to the poor coordination in HIV care in South Africa, it is possible that
some of these infants relocated to another region to receive care with-
out being formally being transferred, which may have led us to over-
estimate true loss to follow-up.
ART has been widely successful in improving health, prolonging life
and reducing HIV transmission events across sub-Saharan Africa. Further-
more, cART adherence in acutely infected women from a similar sociode-
mographic in KwaZulu-Natal with additional support can achieve
excellent outcomes [30]. For the »0.6% of HIV-infected mothers in Kwa-
Zulu-Natal who transmit HIV IU [12] andwho have already been failed by
the PMTCT program, are unlikely to be successful with cART treatment for
their child. In the absence of long-acting therapeutic interventions that
can be implemented very soon after birth, unless these unmet needs are
addressed, infant HIV-relatedmorbidity andmortality will remain high.
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